

FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: BioHarvest Sciences Inc. (the "Issuer").

Trading Symbol: BHSC

Number of Outstanding Listed Securities: 431,399,251

Date: April 12, 2021

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer's obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer's ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

General Instructions

- (a) Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered, nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
- (b) The term "Issuer" includes the Issuer and any of its subsidiaries.
- (c) Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

On March 4, 2021, the Issuer announced that it had reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil.

On March 10, 2021, the Issuer confirmed its listing on the Frankfurt Stock Exchange (also known as the Deutsche Boerse AG) under WKN: A2P3RM and the symbol 8MV. The Frankfurt listing will increase the visibility of the Issuer amongst European investors and will make it easier for both institutional and retail investors across Europe to participate in the market for BioHarvest shares. On March 18, 2021, the Issuer received approval from the Ministry of Health in Israel to include VINIA® (its proprietary red grape cell product) in a health snack bar. Accordingly, the Issuer increased its 2021 forecasted sales orders for VINIA® in Israel to US\$ 1.3M-US \$1.5M. The overall forecast for US sales of the VINIA® dietary supplement will be updated soon after the US launch of VINIA® in May 2021.

On March 22, 2021, the Issuer announced that they have extended the Investor Relations Agreement

with Justin Meikelm who provides investor relations services to the Issuer. The IR Agreement has been extended for an additional 3 years, commencing January 1, 2021, for a monthly fee of \$10,500+GST. As per the agreement, the consultant is eligible for a bonus of up to 3 months of his pay based on the delivery of key aligned performance metrics. The agreement may be terminated by the Issuer on 75 days' notice. On January 12, 2021, as part of his agreement, Justin Meikelm was granted a total of 300,000 incentive stock options exercisable to purchase a common share of the Issuer at a price of \$0.36 per share. The options are vesting quarterly over a 3-year period for a term of 10 years.

On March 22, 2021, the Issuer granted 4,343,800 stock options to the Issuer's Chairman and Director, Dr. Zaki Rakib. The stock options granted are exercisable to purchase a common share of the Issuer at a price of \$0.50 per share for a term of 10 years with a quarterly vesting period over the next 2 years.

On March 25, 2021, the Issuer announced that they have appointed Scott McCune to their Board of Advisors. Scott will leverage his experience to assist the BioHarvest team in building a disruptive and integrated marketing program for the imminent launch of the Issuer's flagship VINIA® product in the US market.

On March 31, 2021, the Issuer invited all shareholders, media, and interested investors to join a Live Video Conference ("Webinar") on Thursday, April 8, 2021 at 2:00 PM Eastern Standard Time (11:00 AM Pacific Standard Time). BioHarvest Sciences CEO Ilan Sobel hosted the event, which included a look forward to the imminent e-commerce launch for VINIA® in the United States, a review of Q1 2021 Israel sales orders performance, and a discussion of progress on the BioHarvest 2021 Growth Plan.

2. Provide a general overview and discussion of the activities of management.

The Issuer's management continues to direct its energy on developing a holistic integrated e-commerce marketing launch plan for its planned launch of VINIA® scheduled for the week commencing May 9, 2021. Management signed an agreement with ShipCalm, a major 3PL operator for the shipment of all its orders across the USA and Canada.

Management is concentrating its efforts on building a "Best in Class" Marketing Mix to drive a disruptive launch of VINIA® and has engaged multiple top creative talents to develop the required marketing materials to be utilized during the launch period.

In addition, in the Israeli market, Management has announced the launch of a VINIA® Health Bar coming in May containing piceid resveratrol and a matrix of key polyphenols equivalent to 2 glasses of wine in each 26-gram Health Bar. Israel, given its market sophistication and maturity, will be used as a test market for the Issuer to validate the performance of its VINIA® Health Bar, prior to entering the US\$ 10 Billion US Snack Bar Market

In March, Management confirmed that the large majority of the structural building of its 20+ Ton manufacturing facility for VINIA® has been completed. Management will now focus its resources on implementing the key systems required for manufacturing to commence at the end of Q3, 2021.

In the Issuer's Cannabis vertical, Management continues to make good progress in advancing its Cannabis R&D and commercialization efforts towards its launch of Cannabis in H1, 2022.

3. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

Not Applicable

4. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

Not Applicable

5. Describe any new business relationships entered into between the Issuer, the Issuer's affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

Not Applicable.

6. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

Not Applicable

7. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

Not Applicable.

8. Describe the acquisition of new customers or loss of customers.

Not Applicable

9. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trademarks.

Not Applicable

10. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

Not Applicable

11. Report on any labour disputes and resolutions of those disputes if applicable.

Not Applicable

12. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

Not Applicable

13. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

Not Applicable

14. Provide details of any securities issued and options or warrants granted.

In March 2021, the Issuer granted the following options:

- a) 880,000 stock options to consultants. The stock options granted are exercisable to purchase a common share of the Issuer at a price of \$0.50 per share for a term of 10 years. 750,000 stock options granted will vest quarterly over a 3-year period and 130,000 granted will vest monthly over 10 months.
- b) 4,343,800 stock options to the Issuer's Chairman and Director, Dr. Zaki Rakib. The stock options granted are exercisable to purchase a common share of the Issuer at a price of \$0.50 per share for a term of 10 years with a quarterly vesting period over the next 2 years.

15. Provide details of any loans to or by Related Persons.

Not Applicable

16. Provide details of any changes in directors, officers or committee members.

Not Applicable

17. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

The Issuer has been impacted by the emerging and ongoing COVID-19 pandemic. The pandemic has made it challenging to run its operations at optimal efficiency levels. All efforts are being taken by the Issuer to minimize any disruption impact across the business operations. Further, COVID 19 has increased consumer demand levels for Health and Wellness related products such as VINIA®, which is owned and produced by the Issuer and the Issuer has reflected this increased demand in its sales forecast for its Israel business.

Certificate Of Compliance

The undersigned hereby certifies that:

- 1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
- 2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
- 3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
- 4. All of the information in this Form 7 Monthly Progress Report is true.

Dated April 12, 2021

Ilan Sobel
Name of Director or Senior Officer

"Ilan Sobel"
Signature

CEO
Official Capacity

| | | |
|--|--|----------------------------|
| Issuer Details | | |
| Name of Issuer | For Month Ended | Date of Report YY/MM/DD |
| BioHarvest Sciences Inc. | March 2021 | 21/04/12 |
| Issuer Address | | |
| 1140 - 625 Howe Street | | |
| City/Province/Postal Code | Issuer Fax No. () | Issuer Telephone No. |
| Vancouver, BC, V6C 2T6 | | (604) 622-1186 |
| Contact Name | Contact Position | Contact Telephone No. |
| Ilan Sobel | CEO | (604) 622-1186 |
| Contact Email Address: ilan@bioharvest.com | Web Site Address www.bioharvest.com | |